IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
Key figures
IBA was founded in 1986.
2021 turnover = EUR 313 million
11% of turnover invested in R&D
1.600+ employees
100.000+ patients treated
600+ accelerators sold
2021 turnover = EUR 313 million
11% of turnover invested in R&D
1.600+ employees
100.000+ patients treated
600+ accelerators sold
Chemin du Cyclotron 3 – 1348 Louvain-la-Neuve
Contact person: Olivier Lechien
https://www.iba-worldwide.com/
info@iba-group.com
+32 10 475 811
IBA
Activities and description
Proton Beam therapy releases the maximum energy within the tumor target area while limiting radiation to the surrounding healthy tissues. Therefore, it has the potential to enable dose escalation in the targeted tumor, without increasing the risk of side effects or long-term complications.
RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers in two ways: with their in-house radioisotope production; and by providing global solutions, from project design to the operation of their facility to produce 18F-FDG, other 18F-labeled compounds (18FCH, 18FLT, Na18f) and future radiopharmaceuticals.
Industrial Solutions develops solutions for applications such as medical device sterilization. Its E-beam and X-Ray solutions enable the medical industry to be significantly more environment-friendly.
In medical imaging and radiotherapy, radiation must be used with great caution and precision. Because the control of the dose is of paramount importance, Dosimetry’s instruments and software are needed to calibrate and control the diagnostic and therapeutic equipment.
Targeted market
IBA Solutions’ growth perspectives are positive with the increased demand for proton therapy solutions, Positron Emission Tomography (PET) and theranostics radiopharmaceuticals, and for sterilization solutions throughout developed and emerging countries.
Ongoing projects/partnerships/collaborations
IBA is involved in several collaboration projects with universities, poles and activity and business partners. While IBA has created the most knowledgeable community in proton therapy, it has also developed a deep global network of industrial, clinical and academic partners. Since 2021, IBA has launch a new strategic R&D partnership with SCK-CEN to enable the production of Actinium-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.